CD22

KEI and UACT Joint Comments to the NIH Regarding Exclusive License to Syncopation for CAR Therapy

Posted on by Claire Cassedy

Knowledge Ecology International (KEI) and the Union for Affordable Cancer Treatment (UACT) submitted comments to the National Institutes of Health (NIH) on Friday July 9, 2021 regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of Monospecific… Continue Reading →

Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma (and NIH Response)

Posted on by Kathryn Ardizzone

(UPDATE: As noted in the comments below, the NIH provided a response to the joint comments submitted on September 5, 2019, well in advance of the close of the comment period on September 15, 2019) On September 19, 2019, Knowledge… Continue Reading →